| Identification | Back Directory | [Name]
3-Piperidinebutanamide, β-[[(2S)-2-[(2-benzofuranylcarbonyl)amino]-3-cyclohexyl-1-oxopropyl]amino]-α,2-dioxo-N-(phenylmethyl)-, (βS,3S)- | [CAS]
2410075-64-6 | [Synonyms]
CTSL/CAPN1-IN-2
3-Piperidinebutanamide, β-[[(2S)-2-[(2-benzofuranylcarbonyl)amino]-3-cyclohexyl-1-oxopropyl]amino]-α,2-dioxo-N-(phenylmethyl)-, (βS,3S)- | [Molecular Formula]
C34H40N4O6 | [MOL File]
2410075-64-6.mol | [Molecular Weight]
600.7 |
| Hazard Information | Back Directory | [Uses]
CTSL/CAPN1-IN-2 (Compound 14b) is an orally active inhibitor of both CTSL and CAPN1, with IC50 values of 6.88 nM and 347.6 nM, respectively. CTSL/CAPN1-IN-2 possesses anti-inflammatory properties and favorable pharmacokinetic characteristics. CTSL/CAPN1-IN-2 exhibits broad-spectrum antiviral activity against coronaviruses by blocking viral entry[1]. | [References]
[1] Xie X, et al. Structure-based design of pan-coronavirus inhibitors targeting host cathepsin L and calpain-1. Signal Transduct Target Ther. 2024 Mar 6;9(1):54. DOI:10.1038/s41392-024-01758-8 |
|
|